profile icon
Prof

Gary Anderson

Professor
Pharmacology And Therapeutics
asthma
COPD
lung disease
treatments for lung disease
science & technology
life sciences & biomedicine
animals
humans
respiratory system
Gary Anderson's Profile Picture
Prof

Gary Anderson

 
Division
Medicine, Dentistry And Health Sciences
 
Primary Interest
Understanding how disease occurs by studying basic mechanisms in experimental models and in patients who volunteer for research
Gary Anderson's Profile Picture
Prof

Gary Anderson

 

Gary P. Anderson, PhD
Gary Anderson is a pharmacologist and immunologist based in the Medical Faculty at the University of Melbourne, Australia, one of the world’s leading research-intensive Universities and Medical Schools (www.unimelb.edu.au) where he is a tenured Professor and Director of the Centre for Lung Health Research.
Gary’s own research has centred on using genetic disease models to understanding molecular mechanisms of disease induction, progression, severity and exacerbation in asthma and COPD.

He co-discovered the role of Fas in lung inflammation, IL-4 in immune biasing in asthma models and the bronchoprotective PAR receptor system in the airway epithelium. Recent research has explored how blood growth factors control innate immunity in asthma and COPD; IL-17 in persistent inflammation; linking mutations in src-kinases to non-T cell determinants of very severe lung disease; plasticity and heterogeneity of lung macrophage progenitors; novel blood biomarkers in COPD exacerbations; molecular determinants of muscle wasting in COPD, GM-CSF as a therapeutic target; genetic reprogramming of lung stem cells and the molecular co-determinants of emphysema and lung cancer; and, the role of SAA in lung inflammation and allosteric block of catabasis. In 2008 he proposed the widely cited endotype (http://en.wikipedia.org/wiki/Endotype) concept of asthma (Lancet). He works closely with clinical colleagues in Melbourne’s preeminent Hospitals, especially the Departments of Respiratory Medicine and Clinical Immunology at the Royal Melbourne Hospital (www.rmh.mh.org.au ), on translational lung disease research. He is the author of more than 150 highly cited manuscripts on lung disease research and is a recipient of the Research Medal of the Thoracic Society of Australia and New Zealand (TSANZ) for his contribution to lung disease research.
Prior to returning in Australia Gary worked in the Swiss Pharmaceuticals Industry (Sandoz and Ciba-Geigy, now Novartis) for about 10 years and he maintains close links with biotechnology and pharmaceutical companies interested in advance lung health. His basic and applied translational work has contributed to the discovery and development of number of new medicines for respiratory disease that are widely used in current clinical practice.
He co-founded, and served as Research Director of, the Cooperative Research Centre for Chronic Inflammatory Diseases (CRC-CID), and has served at executive level on the National Health and Medical Research Council (NHMRC) of Australia. He serves on the Board of Directors of TSANZ, where he is Chair of the Research Committee, and on the Council of the Lung Foundation Australian.

Projects

Displaying the 53 most recent projects by Gary Anderson.

53

Projects

Project Types


32

Research Contracts


21

Research Grant


Scholarly Works

Displaying the 200 most recent scholarly works by Gary Anderson.

News

Displaying the most recent news article by Gary Anderson.

Credentials

Positions


Professor

Pharmacology And Therapeutics

Thoracic Society Of Australia And New Zealand

Thoracic Society of Australia and New Zealand

American Thoracic Society

American Thoracic Society

European Respiratory Society

European Respiratory Society

Education


Master of Fine Art

University of Melbourne

Master of Contemporary Art

University of Melbourne

Doctor of Philosophy

University of Melbourne

Bachelor of Science

University of Melbourne